PCSK9 inhibition: ready for prime time in CKD?

PCSK9 inhibition: ready for prime time in CKD?

Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein conver...

Bibliografiset tiedot
Päätekijät:	Mafham, M, Haynes, R
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Elsevier 2018

Samankaltaisia teoksia

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Tekijä: Preiss, D, et al.
Julkaistu: (2016)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
Tekijä: Sliz, E, et al.
Julkaistu: (2018)

Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
Tekijä: Humphries, SE, et al.
Julkaistu: (2009)

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?
Tekijä: Preiss, D, et al.
Julkaistu: (2017)

Lipid-modifying agents, from statins to PCSK9 inhibitors
Tekijä: Preiss, D, et al.
Julkaistu: (2020)

Renal Denervation: Is It Ready for Prime Time?
Tekijä: Lauder, Lucas, et al.
Julkaistu: (2020)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Tekijä: Preiss, D, et al.
Julkaistu: (2016)

CKD staging--evolution not revolution.
Tekijä: Winearls, C, et al.
Julkaistu: (2010)

C-EPO: ready for prime-time preconditioning?
Tekijä: Kennedy, J, et al.
Julkaistu: (2005)

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Tekijä: Hopewell, J, et al.
Julkaistu: (2017)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Tekijä: Schmidt, A, et al.
Julkaistu: (2019)

Biomarkers in early-stage colorectal cancer: ready for prime time?
Tekijä: Church, D, et al.
Julkaistu: (2012)

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar
Tekijä: Preiss, D, et al.
Julkaistu: (2020)

Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
Tekijä: Gan, ES, et al.
Julkaistu: (2020)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
Tekijä: Nissen, SE, et al.
Julkaistu: (2016)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
Tekijä: Futema, M, et al.
Julkaistu: (2014)

PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
Tekijä: Holmes, M, et al.
Julkaistu: (2024)

Measuring coronary microvascular function: is it finally ready for prime time?
Tekijä: Banning, AP, et al.
Julkaistu: (2019)

Polygenic risk score for embryo selection—not ready for prime time
Tekijä: Polyakov, A, et al.
Julkaistu: (2022)

PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study
Tekijä: Preiss, D, et al.
Julkaistu: (2016)

Is Malaysia ready for an islamist prime minister?
Tekijä: Farish A. Noor
Julkaistu: (2013)

PCSK6 is associated with handedness in individuals with dyslexia.
Tekijä: Scerri, T, et al.
Julkaistu: (2011)

PCSK6 is associated with handedness in individuals with dyslexia
Tekijä: Richardson, A, et al.
Julkaistu: (2011)

In vivo and in vitro effects of phaleria macrocarpa (scheff.) boerl on low density lipoprotein and pcsk9 expression
Tekijä: Chong, Soo Ching
Julkaistu: (2011)

Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
Tekijä: Deshycka, Rhogerry, et al.
Julkaistu: (2022)

Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Tekijä: Maurer, J, et al.
Julkaistu: (2024)

Effects of Long-term, Monthly Administration of the Pcsk9 Inhibitor Evolocumab (Amg 145) in Patients with Dysglycemia or Metabolic Syndrome
Tekijä: Henry, R, et al.
Julkaistu: (2014)

Conventional and genetic evidence on the association between adiposity and CKD
Tekijä: Zhu, P, et al.
Julkaistu: (2020)

Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?
Tekijä: Haynes, R, et al.
Julkaistu: (2013)

Chronic kidney disease: Does serum phosphate predict death and ESRD in CKD patients?
Tekijä: Haynes, R, et al.
Julkaistu: (2013)

Impact of CKD on household income
Tekijä: Morton, R, et al.
Julkaistu: (2017)

Serum free light chains and the risk of ESRD and death in CKD.
Tekijä: Haynes, R, et al.
Julkaistu: (2011)

Serum free light chains and the risk of ESRD and death in CKD
Tekijä: Haynes, R, et al.
Julkaistu: (2011)

Bioimpedance in CKD: an untapped resource?
Tekijä: Mayne, KJ, et al.
Julkaistu: (2022)

Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
Tekijä: Chong, Soo Ching, et al.
Julkaistu: (2011)

Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients.
Tekijä: Kent, S, et al.
Julkaistu: (2013)

Pcsk5 is required in the early cranio-cardiac mesoderm for heart development.
Tekijä: Szumska, D, et al.
Julkaistu: (2017)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
Tekijä: Lamprea-Montealegre, J, et al.
Julkaistu: (2019)

The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Tekijä: Scartezini, M, et al.
Julkaistu: (2007)

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Tekijä: Sattar, N, et al.
Julkaistu: (2016)